75051-55-7

Basic information

• Product Name: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI);tert-butyl 2-(aminooxy)ethylcarbamate;(2-Aminooxyethyl)carbamic acid tert-butyl ester;Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester;tert-butyl N-[2-(aminooxy)ethyl]carbamate
• CAS NO: 75051-55-7
• Molecular Formula: C₇H₁₆N₂O₃
• Molecular Weight: 176.21354
• Product Categories: N-BOC
• Mol File: 75051-55-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 303.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.058±0.06 g/cm3(Predicted)
• PKA: 12.57±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(75051-55-7)
• EPA Substance Registry System: Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI)(75051-55-7)

Safety Data

• Hazardous Substances Data: 75051-55-7(Hazardous Substances Data)

Usage

General Description

Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C6H13NO3. It is also known by its common name, N-tert-Butoxycarbonylhydroxylamine. Carbamic acid, [2-(aminooxy)ethyl]-, 1,1-dimethylethyl ester (9CI) is often used in organic synthesis as a reagent for the protection of amines, particularly in the field of peptide synthesis. It is a white to off-white crystalline solid that is soluble in organic solvents. As a reagent, it is particularly useful for the selective protection of amines in the presence of other functional groups, making it a valuable tool in the development of complex organic molecules. However, it is important to handle and use this compound with caution, as it can be hazardous if not properly managed.

Upstream product

• 87276-51-5 [2-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)-ethyl]carbamic acid tert-butyl ester 
• 60-34-4 methylhydrazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 

Downstream Products

• 1007552-74-0 C₂₃H₂₃BrF₃N₃O₄S₂ 
• 1452466-19-1 {2-[({[(2S,5R)-6-benzyloxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)oxy]ethyl}carbamic acid tert-butyl ester 
• 1596369-01-5 N-(2-aminoethoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide 

Relevant articles and documents

Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure-Activity-Relationships and In Vitro and In Vivo Activities

The current worldwide emergence of carbapenem-resistant enterobacterales (CREs) constitutes an important growing clinical and public health threat. Acquired carbapenemases are the most important determinants of resistance to carbapenems. In the development of the previously reported tricyclic β-lactam skeleton which exhibits potent antibacterial activities against several problematic β-lactamase-producing CREs without a β-lactamase inhibitor, we found that these activities were reduced against clinical isolates with resistance mechanisms other than β-lactamase production. These mechanisms were the reduction of outer membrane permeability with the production of β-lactamases and the insertion of four amino acids into penicillin-binding protein 3. Here, we report the discovery of a potent compound that overcomes these resistance mechanisms by the conversion of the alkoxyimino moiety of the aminothiazole side chain in which a hydrophilic functional group is introduced and the carboxylic acid of the alkoxyimino moiety is converted to reduce the negative charge of the whole molecule from 2 to 1. This potent tricyclic β-lactam is a promising drug candidate for infectious diseases caused by CREs due to its potent therapeutic efficacy in the neutropenic mouse lung infection model and low frequency of producing spontaneously resistant mutants.

1,2,5-oxadiazole derivative used as indoleamine 2,3-dioxygenase inhibitor

The invention belongs to the technical field of 1,2,5-oxadiazole derivatives, and particularly relates to a 1,2,5-oxadiazole derivative or a pharmaceutically acceptable salt thereof which is used as an indoleamine 2,3-dioxygenase inhibitor. The structure of the 1,2,5-oxadiazole derivative or the pharmaceutically acceptable salt thereof used as the IDO inhibitor is shown in the following formula I.The invention provides a general formula compound I with a novel structure. Experimental results show that some compounds have excellent IDO inhibitory activity and permeation performance at the sametime. The compound is expected to be marketed as a tumor molecular immunotherapeutic drug for cancer treatment.

With tumor homing therapeutic polypeptide - drug conjugates and application thereof (by machine translation)

The present invention relates to guide treatment with tumor polypeptide - drug conjugates, polypeptide - drug conjugates preparation method and its application. The polypeptide of the invention - drug conjugates can be specific will PD0325901 analogs to d